Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules,
are currently the cornerstone of pharmacological treatment of atherothrombotic events …

Introduction Aspirin and anti-P2Y12 are widely prescribed in cardiovascular patients, often
in combination with proton pump inhibitors (PPIs) to limit the risk of upper gastrointestinal …

Ischemic stroke is a disease related to abnormal blood flow that leads to brain dysfunction.
The early and late phases of the disease are distinguished. A distinction is made between …

Antiplatelet therapy with P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor,
cangrelor) is a cornerstone of medical therapy after percutaneous coronary interventions …

Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute
coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does …

Background Data from available studies suggest that the presence of ST-elevation
myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor …

High platelet reactivity (HPR) is a risk factor for stent thrombosis, a potentially lethal
complication of percutaneous coronary intervention. HPR is also associated with increased …

The APPLE COPD-ICON2 trial is a prospective 2× 2 factorial, double-blinded proof-of-
concept randomised controlled trial targeting patients with chronic obstructive pulmonary …

Introduction The most common classification of acute myocardial infarction (AMI) is based on
electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is currently the
standard of care for the prevention of ischemic events in patients with acute coronary …